(Q38795740)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27036356%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

title

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27036356%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27036356%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Kevin Outterson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27036356%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

John H Rex

series ordinal

1

1 reference

6 September 2017

Kevin Outterson

series ordinal

2

1 reference

6 September 2017

1 April 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27036356%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

31 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27036356%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27036356%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27036356%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

page(s)

500-505

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27036356%20AND%20SRC:MED&resulttype=core&format=json

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America

31 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Stoking the antibiotic pipeline.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Repairing the broken market for antibiotic innovation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Time for a change: addressing R&D and commercialization challenges for antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Towards new business models for R&D for novel antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Why is big Pharma getting out of antibacterial drug discovery?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

An analysis of FDA-approved drugs for infectious disease: antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Carbapenemase-producing Enterobacteriaceae in Sweden 2007-2013: Experiences from seven years of systematic surveillance and mandatory reporting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Accountable care organizations and evidence-based payment reform

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Adaptive licensing: taking the next step in the evolution of drug approval

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

An international legal framework to address antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

INTRODUCTION: What Will It Take to Address the Global Threat of Antibiotic Resistance?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

Changing patterns of infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900500-9

7 January 2021

10.1016/S1473-3099(15)00500-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27036356%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference